Azenta sale of B Medical Systems delayed by financing

Rhea-AI Filing Summary

Azenta, Inc. reports that the planned sale of B Medical Systems S.À R.L. to Thelema S.À R.L., entered into through a definitive Sale and Purchase Agreement by Azenta Germany GmbH, did not close by the previously expected date of on or before March 31, 2026 because Thelema has not yet secured the required financing. Thelema has indicated it needs additional time to complete its financing arrangements, and the transaction remains subject to all closing conditions, including this financing condition. The parties have not amended or terminated the agreement, and Azenta is evaluating potential paths forward while emphasizing that there can be no assurance the transaction will be completed on a revised timeline or at all.

Positive

• None.

Negative

• Planned divestiture did not close on schedule – The sale of B Medical Systems to Thelema did not close by the previously expected date of on or before March 31, 2026 because the buyer has not yet secured required financing, creating uncertainty about if and when the transaction will be completed.

Insights

M&A and corporate transactions analyst

Financing delay creates material uncertainty around Azenta’s planned divestiture.

The update states that Thelema has not yet secured financing needed to close the sale of B Medical Systems, so the deal did not close by the earlier expectation of on or before March 31, 2026. All closing conditions, including financing, still must be satisfied.

This introduces uncertainty around Azenta’s portfolio plans because completion of the divestiture is no longer tied to a specific timeline and may not occur. The company notes the agreement has not been amended or terminated while it evaluates potential paths forward, indicating options remain open but outcomes are not defined.

The forward-looking statements language underscores that expectations about completing the transaction, including satisfaction of the financing condition, involve risks and may differ from actual results. Subsequent company disclosures may clarify whether the deal proceeds, is renegotiated, or is ultimately terminated.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Previously expected closing timing: On or before March 31, 2026 Notice date from Thelema: March 27, 2026 Form type: Form 8-K

3 metrics

Previously expected closing timing On or before March 31, 2026 Disclosed as the expected closing date for the B Medical Systems transaction, subject to conditions

Notice date from Thelema March 27, 2026 Date Azenta was informed that required financing had not yet been secured

Form type Form 8-K Current report under the Securities Exchange Act disclosing delay of the transaction

Key Terms

Sale and Purchase Agreement, customary closing conditions, financing condition, forward-looking statements, +1 more

5 terms

Sale and Purchase Agreement financial

"entered into a definitive Sale and Purchase Agreement with Thelema S.À R.L."

A sale and purchase agreement is a binding written contract that sets out the exact terms under which one party sells and another buys assets or a business, much like the detailed receipt and instructions you get when buying a house. It matters to investors because it defines the price, what is included, payment timing, and any promises or protections — all of which determine future cash flows, risk, and the value of the companies involved.

customary closing conditions financial

"expected to close on or before March 31, 2026, subject to the satisfaction of customary closing conditions"

"Customary closing conditions" are standard rules or checks that must be met before a business deal can be finalized, like making sure all paperwork is in order or that certain approvals are obtained. They matter because they help protect both parties, ensuring everything is in place and reducing the risk of surprises or problems after the deal is closed.

financing condition financial

"solely as a result of the non‑satisfaction of that financing condition, the Transaction did not close"

Financing condition refers to the overall environment and terms under which borrowing money is available, including interest rates, lending standards, and access to credit. It influences how easily individuals or businesses can obtain funds and at what cost, affecting economic activity and investment decisions. When financing conditions are favorable, borrowing is easier and cheaper; when they tighten, borrowing becomes more difficult and expensive.

forward-looking statements regulatory

"contains forward-looking statements, which involve certain risks and uncertainties"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Securities Exchange Act of 1934 regulatory

"Pursuant to Section 13 or 15(d) the Securities Exchange Act of 1934"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Azenta (AZTA) announce about the B Medical Systems sale?

Azenta announced that the planned sale of B Medical Systems to Thelema did not close by the previously expected date because Thelema has not yet secured required financing. The deal remains subject to all closing conditions, and completion on any revised timeline is uncertain.

Why did the Azenta–Thelema B Medical Systems transaction fail to close on time?

The transaction did not close by the previously expected date because Thelema informed Azenta it has not yet secured the financing required to complete the deal. As a result, the financing condition to closing remains unsatisfied and the sale has been delayed, with timing now uncertain.

Is the agreement to sell B Medical Systems still in effect for Azenta (AZTA)?

Yes. Azenta states that the parties have not amended or terminated the Sale and Purchase Agreement covering the sale of B Medical Systems. However, the transaction is still subject to all closing conditions, including buyer financing, and there is no assurance it will ultimately be completed.

What timeline had Azenta previously given for closing the B Medical Systems transaction?

Azenta previously disclosed that the transaction was expected to close on or before March 31, 2026, subject to customary closing conditions, including Thelema’s securing of final residual financing. That expected timeline has passed without closing because the financing condition remains unsatisfied.

How is Azenta responding to the delay in closing the B Medical Systems sale?

Azenta states it is evaluating potential paths forward with respect to the transaction while Thelema continues its financing efforts. The company emphasizes that completion remains contingent on all closing conditions and cautions there can be no assurance the sale will close on a revised timeline or at all.

What risks does Azenta highlight regarding completion of the B Medical Systems deal?

Azenta notes that statements about expected completion of the transaction are forward-looking and involve risks, including non-satisfaction of the financing condition. The company cautions that actual results could differ and that there can be no assurance the transaction will be completed in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 04:10 PM Learn about SEC filing dates

false 0000933974 0000933974 2026-03-27 2026-03-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 or 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 27, 2026

Azenta, Inc.

(Exact name of registrant as specified in its charter)

Delaware		0-25434		04-3040660
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

200 Summit Drive, 6^th Floor, Burlington, MA 01803

(Address of principal executive offices and Zip Code)

(888) 229-3682

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		AZTA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

As previously disclosed in the Company’s Current Report on Form 8-K filed on December 29, 2025, Azenta Germany GmbH, a wholly owned subsidiary of Azenta, Inc. (the “Company”), entered into a definitive Sale and Purchase Agreement with Thelema S.À R.L. (“Thelema”) relating to the sale of the entire issued share capital of B Medical Systems S.À R.L. (the “Transaction”). The Company previously disclosed that the Transaction was expected to close on or before March 31, 2026, subject to the satisfaction of customary closing conditions, including Thelema’s securing of final residual financing, and that there could be no assurance that the Transaction would be completed.

On March 27, 2026, the Company was informed by Thelema that it has not yet secured the financing required to complete the Transaction and, solely as a result of the non‑satisfaction of that financing condition, the Transaction did not close by March 31, 2026. Thelema has indicated that it requires additional time to complete its financing arrangements. The Transaction remains subject to the satisfaction of all closing conditions, including Thelema’s securing of the required financing, and there can be no assurance that the Transaction will be completed on a revised timeline or at all. The parties have not amended or terminated the Agreement; however, the Company is evaluating potential paths forward with respect to the Transaction while Thelema continues to complete its financing arrangements.

Cautionary Note Regarding Forward-Looking Statements. This Current Report on Form 8-K contains forward-looking statements, which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. For example, statements in Item 8.01 about the expected completion of the Transaction are forward-looking and subject to risks, including non-satisfaction of the financing condition. Although the Company’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this Current Report on Form 8-K speaks only as of the date on which it is made. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether because of new information, future developments or otherwise.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AZENTA, INC.
	/s/ Ephraim Starr
Date: April 2, 2026	Ephraim Starr
	Senior Vice President, General Counsel and Corporate Secretary

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 11.2 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 15.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.3 KB